COPYRIGHT@2020 BY bBHC Corporation Co.,Ltd.ALL RIGHT RESERVED
Stem Cell Treatment & Research Institution
History:
STRI has been all about turning the future into a reality that bears greater meaning for all mankind. Now we stand at a critical turning point where our simple but meaningful discovery is turning into a tangible discovery; thanks to the many collaborators who are looking forward together with us.
2021-2023
2023.
- STRI published the research article :
1. Recovery from BEll's palsy after treatment using uncultured umbilical cord-derived mesenchymal stem cells: A case report". World J Clin Cases. 2023 April 26;11(12):2817-2824. DOI : 10.12998/wjcc.v11.i12.2817
2022.
- Approval Cell Facility Lisencse from Japan FDA
- STRI published the research article :
1. Treatment of syringomyelia using uncultured umbilical cord mesenchymal stem cells: A case report and review of literature
- World J Stem Cells. 2022 April 26; 14(4): 303-309. DOI: 10.4252/wjsc.v14.i4.303
2021.
- Approval Cell Facility License from KFDA
- Approval Human Cell-Related Operation License from KFDA
- STRI published the research articles :
1. "Treatment of acute ischemic stroke by minimally manipulated umbilical cord-derived mesenchymal stem cells transplantation: A case report". World J Stem Cells. 2021 Aug 26;13(8):1151-1159. doi: 10.4252/wjsc.v13.i8.1151.
2. "Psoriasis treatment using minimally manipulated umbilical cord-derived mesenchymal stem cells: A case report". World J Clin Cases. 2021 Aug 16;9(23):6798-6803. doi: 10.12998/wjcc.v9.i23.6798.
3. "Alopecia treatment using minimally manipulated human umbilical cord-derived mesenchymal stem cells: Three case reports and review of literature". World J Clin Cases 2021; 9(15): 3741-3751 [PMID: 34046478 DOI: 10.12998/wjcc.v9.i15.3741].
2018-2020
2020.
- STRI has applied 334 patents related to nEPS over 156 countries and 283 patents are registered in the US, the EU, Israel, Singapore, Australia, Japan, Russia, China, etc.
2018.
- Registered 280 newly Elicited pluripotent stem cells without side effects (nEPS) patents in Korea,US, EU, Australia, Singapore, Japan and Isreal etc.
- Research collaboration with University of Michigan
1999-2017
2016.
- Pre-clinical trialusing hepatocyte-like differentiated cells from nEPS (from Korea) with Seoul National Univ. Bundang Hospital
2015.
- Registered newly Elicited Pluripotent Stem Cells without side effects (nEPS) 16 registered and 94 related patents applied in 146 countries
2014.
- Differentiated nEPS cells into six different organ cells – pancreatic beta cells, neurocytes, hepatocytes, adipocytes, osteoblasts and chondrocytes
2013.
- Discovered the world’s first newly Elicited Pluripotent Stem Cells without side effects (nEPS)
2007.
- Research arm expanded into the Stem Cell Treatment & Research Institute
2000.
- STRI Fundamental Sciences Department launched with 3 sub-divisions
- STRI Life Sciences Research Center receives Korea Industrial Technology Association (KOITA) certification
- STRI Agricultural Life Sciences Research Center completed Plant Products Manufacturing Plant
1999.
- Renamed STRI Stem Cell Research Institute
1989-1998
1997.
- STC Nara opens manufacturing plant in Cheonan
1995.
- Established STC Agricultural Life Sciences Research Center
1989.
- Established STRI Life Sciences Research Center (with the core values of Soul, Treatment & Cell to contribute to mankind by developing stem cell based therapy with a righteous mind.)
